

International Textbook of Diabetes Mellitus, 4th Ed., Chapter 19 - Pathogenesis of nonalcoholic fatty liver disease (NAFLD)

References:

1. Chalasani N, Younossi Z, Lavine JE, et al.: The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. *Gastroenterology* 2012;142(7):1592–160
2. Browning JD, Szczepaniak LS, Dobbins R, et al.: Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. *Hepatology* 2004;40(6):1387–1395.
3. Kotronen A, Westerbacka J, Bergholm R, et al.: Liver fat in the metabolic syndrome. *Journal of Clinical Endocrinology and Metabolism* 2007;92(9):3490–3497.
4. Clark JM, Brancati FL, Diehl AM: The prevalence and etiology of elevated aminotransferase levels in the United States. *American Journal of Gastroenterology* 2003;98(5):960–967.
5. Younossi ZM, Stepanova M, Afendy M, et al.: Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. *Clinical Gastroenterology and Hepatology* 2011;9(6):524–530.e1; quiz e60.
6. Vernon G, Baranova A, Younossi ZM: Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. *Alimentary Pharmacology & Therapeutics* 2011;34(3):274–285.
7. Brunt EM, Kleiner DE, Wilson LA, et al.; Network NCR. Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings. *Hepatology* 2011;53(3):810–820.
8. Anstee QM, Targher G, Day CP: Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. *Nature Reviews Gastroenterology & Hepatology* 2013;10(6):330–344.
9. Starley BQ, Calcagno CJ, Harrison SA: Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. *Hepatology* 2010;51(5):1820–1832.
10. Charlton MR, Burns JM, Pedersen RA, et al.: Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. *Gastroenterology* 2011;141(4):1249–1253.
11. Dyson J, Jaques B, Chattopadhyay D, et al.: Hepatocellular cancer: the impact of obesity, type 2 diabetes and a multidisciplinary team. *Journal of Hepatology* 2014;60:110–117.
12. Torres DM, Harrison SA: Nonalcoholic steatohepatitis and noncirrhotic hepatocellular carcinoma: fertile soil. *Seminars in Liver Disease* 2012;32(1):30–38.
13. Yu J, Shen J, Sun TT, et al.: Obesity, insulin resistance, NASH and hepatocellular carcinoma. *Seminars in Cancer Biology* 2013; 23(6 Pt B):483–491.
14. Trepo E, Nahon P, Bontempi G, et al.: Association between the PNPLA3 (rs738409C>G) variant and hepatocellular carcinoma: evidence from a meta-analysis of individual participant data. *Hepatology* 2013 Oct 1; doi: 10.1002/hep.26767. [Epub ahead of print]

15. Seppala-Lindroos A, Vehkavaara S, Hakkinen AM, et al.: Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. *Journal of Clinical Endocrinology and Metabolism* 2002;87(7):3023–3028.
16. Adiels M, Westerbacka J, Soro-Paavonen A, et al.: Acute suppression of VLDL1 secretion rate by insulin is associated with hepatic fat content and insulin resistance. *Diabetologia* 2007;50(11):2356–2365.
17. Targher G, Chonchol M, Miele L, et al.: Nonalcoholic fatty liver disease as a contributor to hypercoagulation and thrombophilia in the metabolic syndrome. *Seminars in Thrombosis and Hemostasis* 2009; 35(3):277–287.
18. Donnelly KL, Smith CI, Schwarzenberg SJ, et al.: Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. *Journal of Clinical Investigation* 2005; 115(5):1343–1351.
19. Lambert JE, Ramos-Roman MA, Browning JD, Parks EJ: Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease. *Gastroenterology* 2014; 146(3):726–735.
20. Kotronen A, Juurinen L, Tiikkainen M, et al.: Increased liver fat, impaired insulin clearance, and hepatic and adipose tissue insulin resistance in type 2 diabetes. *Gastroenterology* 2008;135(1): 122–130.
21. Gastaldelli A, Cusi K, Pettiti M, et al.: Relationship between hepatic/ visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects. *Gastroenterology* 2007;133(2):496–506.
22. Lazo M, Hernaez R, Eberhardt MS, et al.: Prevalence of nonalcoholic fatty liver disease in the United States: the third national health and nutrition examination survey, 1988–1994. *American Journal of Epidemiology* 2013;178(1):38–45.
23. Xu C, Yu C, Ma H, et al.: Prevalence and risk factors for the development of nonalcoholic fatty liver disease in a nonobese Chinese population: the Zhejiang Zhenhai Study. *American Journal of Gastroenterology* 2013;108(8):1299–1304.
24. Centis E, Marzocchi R, Di Domizio S, et al.: The effect of lifestyle changes in non-alcoholic fatty liver disease. *Digestive Diseases* 2010;28(1):267–273.
25. Rabl C, Campos GM: The impact of bariatric surgery on nonalcoholic steatohepatitis. *Seminars in Liver Disease* 2012;32(1):80–91.
26. Trayhurn P: Hypoxia and adipose tissue function and dysfunction in obesity. *Physiological Reviews* 2013;93(1):1–21.
27. Weisberg SP, McCann D, Desai M, et al.: Obesity is associated with macrophage accumulation in adipose tissue. *Journal of Clinical Investigation* 2003;112(12):1796–1808.
28. Turer AT, Scherer PE: Adiponectin: mechanistic insights and clinical implications. *Diabetologia* 2012;55(9):2319–2326.
29. Kotronen A, Seppala-Lindroos A, Bergholm R, Yki-Jarvinen H: Tissue specificity of insulin resistance in humans: fat in the liver rather than muscle is associated with features of the metabolic syndrome. *Diabetologia* 2008;51(1):130–138.
30. Machado MV, Cortez-Pinto H: Gut microbiota and nonalcoholic fatty liver disease. *Annals of Hepatology* 2012;11(4):440–449.
31. Vague J: La differentiation sexuelle. Facteur determinant des formes de l'obésité. *La Presse medicale* 1947;55(30):339.
32. Tchernof A, Despres JP: Pathophysiology of human visceral obesity: an update. *Physiological Reviews* 2013;93(1):359–404.
33. Frayn KN: Visceral fat and insulin resistance--causative or correlative? *The British Journal of Nutrition* 2000;83(Suppl 1):S71–77.

34. Seidell JC, Bouchard C: Visceral fat in relation to health: is it a major culprit or simply an innocent bystander? *International Journal of Obesity and Related Metabolic Disorders* 1997;21(8):626–631.
35. Fabbrini E, Magkos F, Mohammed BS, et al.: Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity. *PNAS* 2009;106(36):15430–15435.
36. Fabbrini E, Tamboli RA, Magkos F, et al.: Surgical removal of omental fat does not improve insulin sensitivity and cardiovascular risk factors in obese adults. *Gastroenterology* 2010;139(2):448–455.
37. Musso G, Cassader M, Olivetti C, et al.: Association of obstructive sleep apnoea with the presence and severity of non-alcoholic fatty liver disease. A systematic review and meta-analysis. *Obesity Reviews* 2013;14(5):417–431.
38. Sookoian S, Pirola CJ: Obstructive sleep apnea is associated with fatty liver and abnormal liver enzymes: a meta-analysis. *Obesity Surgery* 2013;23(11):1815–1825.
39. Sun K, Tordjman J, Clement K, Scherer PE: Fibrosis and adipose tissue dysfunction. *Cell Metabolism* 2013;18(4):470–477.
40. Jones H, Sprung VS, Pugh CJ, et al.: Polycystic ovary syndrome with hyperandrogenism is characterized by an increased risk of hepatic steatosis compared to nonhyperandrogenic PCOS phenotypes and healthy controls, independent of obesity and insulin resistance. *Journal of Clinical Endocrinology and Metabolism* 2012;97(10):3709–3716.
41. Hu FB, Malik VS: Sugar-sweetened beverages and risk of obesity and type 2 diabetes: epidemiologic evidence. *Physiology & Behavior* 2010;100(1):47–54.
42. Abdelmalek MF, Suzuki A, Guy C, et al.: Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease. *Hepatology* 2010;51(6):1961–1971.
43. Aarsland A, Wolfe RR: Hepatic secretion of VLDL fatty acids during stimulated lipogenesis in men. *Journal of Lipid Research* 1998;39(6):1280–1286.
44. Kotronen A, Seppanen-Laakso T, Westerbacka J, et al.: Hepatic stearoyl-CoA desaturase (SCD)-1 activity and diacylglycerol but not ceramide concentrations are increased in the nonalcoholic human fatty liver. *Diabetes* 2009;58(1):203–208.
45. Westerbacka J, Kotronen A, Fielding BA, et al.: Splanchnic balance of free fatty acids, endocannabinoids, and lipids in subjects with nonalcoholic fatty liver disease. *Gastroenterology* 2010;139(6):1961–1971.e1.
46. Neuschwander-Tetri BA: Carbohydrate intake and nonalcoholic fatty liver disease. *Current Opinion in Clinical Nutrition and Metabolic Care* 2013;16(4):446–452.
47. Sevastianova K, Santos A, Kotronen A, et al.: Effect of short-term carbohydrate overfeeding and long-term weight loss on liver fat in overweight humans. *American Journal of Clinical Nutrition* 2012;96(4):727–734.
48. Mensink RP, Zock PL, Kester AD, Katan MB: Effects of dietary fatty acids and carbohydrates on the ratio of serum total to HDL cholesterol and on serum lipids and apolipoproteins: a meta-analysis of 60 controlled trials. *American Journal of Clinical Nutrition* 2003;77(5):1146–1155.
49. Schwarz JM, Linfoot P, Dare D, Aghajanian K: Hepatic de novo lipogenesis in normoinsulinemic and hyperinsulinemic subjects consuming high-fat, low-carbohydrate and low-fat, high-carbohydrate isoenergetic diets. *American Journal of Clinical Nutrition* 2003;77(1):43–50.

50. Johnson NA, Keating SE, George J: Exercise and the liver: implications for therapy in fatty liver disorders. *Seminars in Liver Disease* 2012;32(1):65–79.
51. Bae JC, Suh S, Park SE, et al.: Regular exercise is associated with a reduction in the risk of NAFLD and decreased liver enzymes in individuals with NAFLD independent of obesity in Korean adults. *PLoS One* 2012;7(10):e46819.
52. Sullivan S, Kirk EP, Mittendorfer B, et al.: Randomized trial of exercise effect on intrahepatic triglyceride content and lipid kinetics in nonalcoholic fatty liver disease. *Hepatology* 2012;55(6): 1738–1745.
53. Kirk E, Reeds DN, Finck BN, et al.: Dietary fat and carbohydrates differentially alter insulin sensitivity during caloric restriction. *Gastroenterology* 2009;136(5):1552–1560.
54. Rabol R, Petersen KF, Dufour S, et al.: Reversal of muscle insulin resistance with exercise reduces postprandial hepatic de novo lipogenesis in insulin resistant individuals. *PNAS* 2011;108(33):13705–13709.
55. Schwimmer JB, Celedon MA, Lavine JE, et al.: Heritability of nonalcoholic fatty liver disease. *Gastroenterology* 2009;136(5): 1585–1592.
56. Makkonen J, Pietilainen KH, Rissanen A, et al.: Genetic factors contribute to variation in serum alanine aminotransferase activity independent of obesity and alcohol: a study in monozygotic and dizygotic twins. *Journal of Hepatology* 2009;50(5):1035–1042.
57. Weston SR, Leyden W, Murphy R, et al.: Racial and ethnic distribution of nonalcoholic fatty liver in persons with newly diagnosed chronic liver disease. *Hepatology* 2005;41(2):372–379.
58. Romeo S, Kozlitina J, Xing C, et al.: Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. *Nature Genetics* 2008;40(12):1461–1465.
59. Sookoian S, Pirola CJ: Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease. *Hepatology* 2011;53(6):1883–1894.
60. Anstee QM, Day CP: The genetics of NAFLD. *Nature Reviews Gastroenterology & Hepatology* 2013;10(11):645–655.
61. Kantartzis K, Peter A, Machicao F, et al.: Dissociation between fatty liver and insulin resistance in humans carrying a variant of the patatin-like phospholipase 3 gene. *Diabetes* 2009; 58(11):2616–2623.
62. Peng XE, Wu YL, Lin SW, et al.: Genetic variants in PNPLA3 and risk of non-alcoholic fatty liver disease in a Han Chinese population. *PLoS One* 2012;7(11):e50256.
63. Lin YC, Chang PF, Chang MH, Ni YH: A common variant in the peroxisome proliferator-activated receptor-gamma coactivator-1alpha gene is associated with nonalcoholic fatty liver disease in obese children. *American Journal of Clinical Nutrition* 2013;97(2):326–331.
64. Huang Y, Cohen JC, Hobbs HH: Expression and characterization of a PNPLA3 protein isoform (I148M) associated with nonalcoholic fatty liver disease. *The Journal of Biological Chemistry* 2011;286(43):37085–37093.
65. Kumari M, Schoiswohl G, Chitralu C, et al.: Adiponutrin functions as a nutritionally regulated lysophosphatidic acid acyltransferase. *Cell Metabolism* 2012;15(5):691–702.
66. Lallukka S, Sevastianova K, Perttinen J, et al.: Adipose tissue is inflamed in NAFLD due to obesity but not in NAFLD due to genetic variation in PNPLA3. *Diabetologia* 2013;56(4):886–892.

67. Yki-Järvinen H: Pathophysiology of type 2 diabetes. In: Wass JAH, Stewart PM (eds.) Oxford Textbook of Endocrinology and Diabetes. Oxford: Oxford University Press, 2011, pp. 1740–1748.
68. Fabbrini E, Mohammed BS, Magkos F, et al.: Alterations in adipose tissue and hepatic lipid kinetics in obese men and women with nonalcoholic fatty liver disease. *Gastroenterology* 2008;134(2):424–431.
69. Adiels M, Olofsson SO, Taskinen MR, Boren J: Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome. *Arteriosclerosis, Thrombosis, and Vascular Biology* 2008;28(7):1225–1236.
70. Kalme T, Seppala M, Qiao Q, et al.: Sex hormone-binding globulin and insulin-like growth factor-binding protein-1 as indicators of metabolic syndrome, cardiovascular risk, and mortality in elderly men. *Journal of Clinical Endocrinology and Metabolism* 2005;90(3):1550–1556.
71. Simonen P, Kotronen A, Hallikainen M, et al.: Cholesterol synthesis is increased and absorption decreased in non-alcoholic fatty liver disease independent of obesity. *Journal of Hepatology* 2011;54(1):153–159.
72. Min HK, Kapoor A, Fuchs M, et al.: Increased hepatic synthesis and dysregulation of cholesterol metabolism is associated with the severity of nonalcoholic fatty liver disease. *Cell Metabolism* 2012;15(5):665–674.
73. Angulo P, Hui JM, Marchesini G, et al.: The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. *Hepatology* 2007;45(4):846–854.
74. Angulo P, Bugianesi E, Bjornsson ES, et al.: Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease. *Gastroenterology* 2013;145(4):782–789.e4.